Search Results
Your search for ,Few matches 3119 pages
Showing 1151 - 1200Boswellia
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, focus on the herbal extract...
Reflections on Long-Term Outcomes With BRAF/MEK Inhibition in Advanced Melanoma
For the treatment of BRAF V600-mutated advanced melanoma, we now have three BRAF/MEK inhibitor combinations that are approved by the U.S. Food and Drug Administration: dabrafenib/trametinib, vemurafenib/cobimetinib, and encorafenib/binimetinib. Although the toxicity profiles for these combinations ...
Targeted Treatment Advances in Cholangiocarcinoma
For one of the rarest and most aggressive of tumors—cholangiocarcinoma—two novel molecularly targeted agents yielded encouraging outcomes in advanced disease in studies reported at the European Society for Medical Oncology (ESMO) Congress 2019. In the phase III ClarIDHy trial, the risk of disease...
ESMO Congress 2019 Offers a Global Stage for Important Clinical Data
The European Society for Medical Oncology (ESMO) Congress 2019, held September 27 to October 1 in Barcelona, welcomed clinicians, researchers, journalists, and exhibitors from around the world to hear advances across the oncology spectrum, in both clinical medicine and basic research. For this...
Financial Burdens of Patients With Cirrhosis and Impact on Screening for HCC
Data from a new study presented by Singal et al at The Liver Meeting found that patients with cirrhosis in the United States have substantial financial burden and this is associated with underuse of surveillance for hepatocellular carcinoma (HCC) (Abstract 201). Improved intervention strategies are ...
Remembering Craig Alguire
It is with great sadness that we report Craig Alguire, MD, 42, died on October 11, 2019, at his home in Grand Rapids, Michigan. Diagnosed with grade 4 glioblastoma multiforme in 2015, Dr. Alguire chronicled the effects the cancer was having on his life in his Patient’s Corner column, published in...
Pioneering Breast Surgeon and NSABP Chair, Bernard Fisher, MD, Dies at 101
American physicist and philosopher Thomas Kuhn coined the term “paradigm shift” to connote a fundamental change in the basic concepts and practices of a standard scientific discipline. They are few and far between. To convince the entrenched oncologic surgery community in the 1960s and 1970s that...
2019 NCRI: Use of Mendelian Randomization to Determine Role of Human Gut Microbiome in Colorectal Cancer Development
A study using a technique called Mendelian randomization to investigate the causal role played by bacteria in the development of colorectal cancer was presented at the 2019 National Cancer Research Institute (NCRI) Cancer Conference. First study author Kaitlin Wade, PhD, of the University of...
Lorlatinib in Advanced ROS1-Positive NSCLC
As reported by Alice T. Shaw, MD, and colleagues in The Lancet Oncology, a phase I/II trial has shown overall and intracranial activity of the third-generation ALK and ROS1 tyrosine kinase inhibitor lorlatinib in patients with advanced ROS1-positive non–small cell lung cancer (NSCLC). Lorlatinib...
How Cancer.Net Is Changing to Help Young Adults and Teenagers With Cancer
A diagnosis of cancer always comes as a surprise. Life does not prepare any of us for telling our friends and family that we have cancer, and this can be especially difficult for young adults and teenagers. Cancer interrupts their lives at a time when it is least expected. Life goals,...
The Art of Medicine: Our Role as Patient Advocates
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Debating the Role of Chemoimmunotherapy in the First-Line Setting of CLL
The advent of new targeted agents for chronic lymphocytic leukemia (CLL) has ushered in a golden age of treatment, leading to longer, more durable periods of disease control. Not all oncologists are convinced, however, that improvements in progression-free survival alone warrant dispensing with...
The Future of the Radiation Abscopal Response
“Two roads diverged in a wood, and I—I took the one less traveled by,And that has made all the difference.” –Robert Frost One of the first patients I encountered after residency was a 26-year-old woman with a single brain metastasis from melanoma. For anonymity, let’s call her Anna. Anna had just...
Virtual Molecular Tumor Boards May Help to Efficiently Deliver Precision Medicine to Patients
Using virtual, cloud-based, interconnected computing techniques applied to 51,000 variables, researchers reduced the time needed to assess a patient’s tumor profile and suitability for clinical trials from 14 to 4 days. This method also increased the number of cases that could be assessed compared...
Ariel Hollinshead Hyun, PhD, a Pioneer in Cancer Vaccines, Dies at Age 90
Inspiration comes in many forms. For cancer researcher Ariel Hollinshead Hyun, PhD, known professionally as Dr. Hollinshead, it came at the age of 15, when she was captivated by Paul de Kruif’s book Microbe Hunters. She was fascinated by the lives of early bacteriologists detailed in the book and...
Cancer Taught Me What It Means to Be a Man
Let’s face it, men don’t go to the doctor as often as we should. At least that has been my experience. I felt compelled to finally make an appointment with my primary care physician after I began working as a research assistant at the Smidt Heart Institute at Cedars-Sinai in 2014, as it felt...
A Tale of Two Eugenes
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Researchers Examine the Rise in HPV-Related Oropharyngeal Cancers
Human papillomavirus (HPV) causes nearly all cervical cancers and is attributed to some cancers of the vagina, vulva, penis, anus, and oropharynx. Although most HPV infections are asymptomatic and usually resolve within 1 to 2 years, persistent infections can lead to precancer and cancer. According ...
City of Hope Researchers Receive Awards and Grants
City of Hope recently announced that several of its researchers and faculty have been named as the recipients of several awards and grants. These accolades recognize individuals for their work in their respective fields of human genetics education, genomic research, and leptomeningeal disease....
Younger, Fit Patients With CLL: Goal Remains Undetectable Minimal Residual Disease and Time-Limited Therapy
As reviewed in this issue of The ASCO Post, Shanafelt and colleagues recently published the interim analysis of E1912, a U.S. Intergroup–led randomized phase III trial comparing ibrutinib/rituximab, followed by ibrutinib to disease progression vs 6 months of fludarabine, cyclophosphamide, and...
Reflecting on My First National Presentation
I gave my first national presentation of my original clinical research on a topic that was to become a professional obsession: finding a cure for esophageal cancer. (Spoiler, I failed.) It was late May 1982. Writing about this now is undoubtedly predicated on my recent retirement, my desire to...
Graviola
GUEST EDITOR Integrative Oncology is guest edited by Jun J. Mao, MD, MSCE, Laurance S. Rockefeller Chair in Integrative Medicine and Chief of Integrative Medicine Service at Memorial Sloan Kettering Cancer Center, New York. The ASCO Post’s Integrative Oncology series is intended to facilitate...
Early Research on Novel Interleukin-12 Gene Therapy in Glioblastoma
Recurrent high-grade glioblastoma has a poor prognosis, with a median overall survival of 6 to 9 months. Treatment is limited, partly because immunotherapy has not yet been shown to be effective in the immunosuppressive microenvironment of this tumor. A novel treatment approach involving...
FDA Pipeline: Advances in Prostate Cancer, Urothelial Cancer, Myelofibrosis, and More
In the past few weeks, the U.S. Food and Drug Administration (FDA) has issued regulatory decisions in prostate cancer, urothelial cancer, myelofibrosis, breast cancer, pediatric brain cancer, leukemia, and skin cancer. Breakthrough Therapy Designation for Niraparib in Metastatic...
Expert Point of View: Robert Doebele, MD, PhD, and Roy S. Herbst, MD, PhD
Discussant of the LIBRETTO-001 trial, Robert Doebele, MD, PhD, of the University of Colorado Anschutz Medical Campus in Aurora, Colorado, was enthusiastic about the response rates reported in this preliminary trial. “Older trials of multikinase inhibitors have shown response rates in the range of ...
Older Sexual and Gender Minorities With Cancer: A Population Hidden in the Open
The term “sexual and gender minorities” encompasses people whose sexual orientation, gender identity and expression, or reproductive development varies from traditional, societal, cultural, or physiologic norms1 and includes lesbian, gay, bisexual, transgender, and queer (LGBTQ) people. More than 3 ...
Durvalumab Plus Chemotherapy: New Option for Extensive-Stage SCLC
The addition of the immune checkpoint inhibitor durvalumab to standard therapy significantly improved overall survival vs standard therapy alone for patients with previously untreated extensive-stage small cell lung cancer (SCLC), according to a preplanned interim analysis of the phase III CASPIAN...
Greater Consensus From Global Experts on Controversies in Prostate Cancer
In late August, experts from around the globe convened in Basel, Switzerland, at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) to discuss controversial areas related to the management of advanced prostate cancer. Although the full proceedings of the conference will be published in...
Early Research on Novel Interleukin-12 ‘Gene Therapy’ in Glioblastoma
Recurrent high-grade glioblastoma has a poor prognosis, with a median overall survival of 6 to 9 months. Treatment is limited, partly because immunotherapy has not yet been shown to be effective in the immunosuppressive microenvironment of this tumor. A novel treatment approach involving...
ADMIRAL Study Finds Gilteritinib Effective Across Mutation Cohorts of Acute Myeloid Leukemia
The novel FLT3 inhibitor gilteritinib prolonged survival in patients with FLT3-mutated relapsed or refractory acute myeloid leukemia (AML) across all mutation cohorts, including NPM1, DNMT3A, DNMT3A/NPM1, and WT1, with the greatest benefit seen in patients with NPM1 and DNMT3A co-mutations,...
Raising the Quality of Cancer Care Globally
ASCO’s global vision is, “A world where cancer is prevented or cured, and every survivor is healthy.” In its work toward achieving this vision, the Society offers a robust portfolio of programs that are continually expanding around the world that improve access to quality cancer care, support...
Investigating the Inflammatory Mechanisms That May Be Causing Prostate Cancer in World Trade Center First Responders
The terrorist attacks on September 11, 2001*, on the World Trade Center in New York City resulted in the deaths of more than 2,700 people.1 Nearly 2 decades later, that number may soon be exceeded by the more than 2,000 deaths—and climbing—of first responders to the attack, including firefighters,...
The Fight Against Breast Cancer Illustrates the Health-Care Challenges of Women in Poverty
"Of all the forms of inequality, injustice in health is the most shocking and the most inhumane….” —Dr. Martin Luther King, Jr Progress has been made in expanding access to health care for low-income populations, but the quality of care still lags behind and can result in less successful outcomes...
Finding a New Focus After Cancer
In the early fall of 2015, my daughter and I were on our way to our favorite nail salon to get picture-perfect ready for a gala later that evening at Lincoln Center for the Performing Arts in New York, when I got a call from my gynecologist saying I had “flunked my Pap test.” The Pap smear showed...
Personalizing Medicine
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Patient-Centered Initiatives at the FDA
OCE Insights is a periodic column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this first installment, Vishal Bhatnagar, MD, Acting Associate Director of Patient Outcomes; Bellinda King-Kallimanis, PhD, Senior...
Suboptimal Insurance Linked to Worse Survival Outcomes in Positive Clinical Trials
Findings from a recent SWOG study could cast doubt on the generalizability of treatment effects observed in positive clinical trials, especially among underinsured patients. According to data presented at the 2019 ASCO Quality Care Symposium,1 patients with Medicaid or no insurance had no observed...
AACR Cancer Progress Report 2019 Released
Today, the American Association for Cancer Research (AACR) released the AACR Cancer Progress Report 2019, which highlights how research largely supported by federal investments in the National Institutes of Health (NIH) is spurring improvements in public health and innovations across the spectrum...
Targeting an Important Tumor Vulnerability With Maintenance Olaparib in Germline BRCA-Mutated Pancreatic Cancer
In the POLO trial, which is discussed in this issue of The ASCO Post, Golan and colleagues evaluated the potential benefit of maintenance olaparib after disease stability or response to a minimum of 4 months of platinum-based chemotherapy in patients with metastatic pancreatic cancer and a...
ASTRO 2019: Long-Term Hormone Therapy May Increase Other-Cause Mortality in Men With Prostate Cancer Receiving Early Salvage Radiotherapy
Findings from the randomized phase III NRG Oncology/RTOG 9601 trial were initially reported in 2017, and showed that the addition of 2 years of antiandrogen therapy to postsurgical radiation treatment for men with recurrent prostate cancer increased their long-term overall survival rate. That study ...
ASTRO 2019: Effect of Closure of Women’s Health Clinics From 2010 to 2013 on Cervical Cancer Screening and Detection
Following the closure of nearly 100 women’s health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer; more women were diagnosed with advanced stages of the disease; and disease mortality rates rose. Findings from a new analysis combining several...
WCLC 2019: Declaration From IASLC on Tobacco Cessation After Cancer Diagnosis
The International Association for the Study of Lung Cancer (IASLC) used the platform of the 2019 World Conference on Lung Cancer (WCLC) to call attention to the importance of tobacco cessation after cancer diagnosis and urged all physicians to screen patients with cancer for tobacco use and...
Oncology Communications Online: Pause and Think Before Hitting ‘Send’
The emergence of online technologies over the past few decades has fundamentally changed the way society communicates and shares information. This sea change has also had profound influence on the practice of medicine, from real-time information-sharing among colleagues, to having instant access...
John Hansen, MD, Transplant Expert Who Founded Volunteer Donor Registries, Dies at 76
Over the past few decades, our understanding of transplant immunology has moved from basic allograft rejection to the current molecular level that offers life-saving treatments for patients with cancer. The scientific elegance of this remarkable therapy’s arc from experimental to standard of care...
Not for the Squeamish: Surgery in the 19th Century
Imagine undergoing major surgery in a grimy operating room without any form of antisepsis. That was the grim reality in the 1800s, when the ruling theory was that damage from “bad air” was responsible for infections in surgical wounds. Hospitals simply aired out the surgical wards at midday to...
Doctor, Where Art Thou?
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Insightful Advice From a College Advisor Leads to an Unexpected Career in Oncology
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Tatiana M. Prowell, MD, who currently serves as Associate Professor of Oncology in the Breast Cancer Program at the Johns Hopkins Kimmel Comprehensive Cancer Center and as a Medical Officer and...
How Patient Advocacy Is Integral to High-Quality Oncology Care
Karen M. Winkfield, MD, PhD, has made patient advocacy—with a specific emphasis on health equity and access to high-quality care—front and center of her oncology practice since she completed her residency at the Harvard Radiation Oncology Program in Boston, where she noticed that most of the...
WCLC 2019: Safety and Toxicity of AMG 510 for KRAS G12C–Mutated, Advanced NSCLC
In a clinical trial testing the toxicity of a KRAS inhibitor, the treatment demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non–small cell lung cancer (NSCLC) harboring a KRAS G12C mutation. The research was presented by Govindan et al at the...
Does PTSD Increase the Risk of Developing Ovarian Cancer?
Women who experienced six or more symptoms of posttraumatic stress disorder (PTSD) at some point in life had a twofold greater risk of developing ovarian cancer compared with women who never experienced any PTSD symptoms. These findings were published by Roberts et al in Cancer Research. The...
